A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Iman El‐Hariry(GlaxoSmithKline (United Kingdom)), Dominique Rosine(GlaxoSmithKline (United Kingdom)), Andrew P. Beelen(United Therapeutics (United States)), C. Nutting(Royal Marsden NHS Foundation Trust), Jean Bourhis(University of Lausanne), Andrew G. Stead(GlaxoSmithKline (United Kingdom)), Sharon Gardiner(GlaxoSmithKline (United Kingdom)), M. S. Berger(Duke University), A Theodosiou(GlaxoSmithKline (United Kingdom))
Cited by 32
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
|Journal of Clinical Oncology|2010|806